Pontchartrain Cancer Center | Association Partnerships

Looking at the results of study assessing performing blood-based host immune classifier proteomic testing in patients with non–small cell lung cancer shows the potential for predicting the success of immunotherapy based on a patient’s biomarkers.

In an interview with Targeted Oncology, David Oubre, MD discussed the use of liquid biopsy to identify prognostic and predictive biomarkers in patients with non–small cell lung cancer. He also explained the results and implications of the INSIGHT study.